PowerPointPrsentation

1
ECIL 1 Introduction
2

• The ECIL 1 is the first European Conference on
  Infections in Leukemia which has been held in
  Juan-les-Pins, France, on Sept.30-Oct.1, 2005
• The ECIL 1 is a common initiative of
• the Infectious Diseases Working Party of the
  EBMT
• the Infectious Diseases Group of the EORTC
• - the Supportive Care group of the European
  LeukemiaNet
• - the ImmunoCompromised Host Society

3

• Objectives
• Elaborate European guidelines on prophylaxis,
  and treatment of infectious complications in
  leukemic patients
• Obtain information about what are current
  management strategies in Europe
• Favor communication between groups
• Define new areas of clinical research

4
Six topics were addressed at ECIL 1
I Fluoroquinolone prophylaxis in neutropenic
patients
II Aminoglycosides in febrile neutropenia
III Glycopeptides and other antiGram
antibiotics in febrile neutropenia
IV Empirical antifungal treatment for
persistent fever in neutropenic patients
V Antifungal prophylaxis
VI Antifungal therapy (Aspergillus and Candida)
5
Working Groups
6
METHODS (I)
1 Questions proposed by the organization
committee and redefined by each group 2
Population explored Leukemic, adults,
neutropenic (lt500/mm3), Auto- and Allo SCT
recipients Key words leukemia, neutropenia
MeSH Sources Medline, PubMed, Cochrane Library,
Abstracts of ASH, ICAAC, ASCO, ECMID, and EBMT
2002-2005. 3 Endpoints overall mortality,
mortality due to infections, breakthrough
infections, safety, emergence of resistant
organisms, costs ? others/group
7
METHODS (II)
4 Literature review Randomized trials,
Meta-analyses, open studies , review articles,
treatment guidelines 5 Grading the level of
evidence and level of recommendation CDC
grading system 6 Identify unsolved questions
and new areas of research
8
CDC Grading system
9
QUESTIONNAIRE
Designed to answer questions on management of
hematology patients on the 6 topics, sent by
_at_mail with the invitation to all participants 38
answers from 20 countries - mostly
hematologists (66), heads or chief residents
(73), from university hospitals (76) - Group
affiliations EORTC IDG 63.9 EBMT IDWP
44.4 ICHS 38.9 ELN 25 Thanks to
Marianne Paesmans, EORTC Data Center, for data
collection and analysis of the questionnaire.

10
Sept 30-Oct 1st, 2005

• Presentation of the results of the questionnaires
  and of the conclusions of each working group in
  plenary sessions
• Discussion of each topic with the Conference
  attendees
• Revision on site by the working groups according
  to the discussions and 2nd discussion in plenary
  session until consensus

11
Data available from October 1, to December 31,
2005

• Commented in the final manuscripts
• Provisional recommendation and grading from the
  working groups and chairs, pending the update of
  ECIL 2007 for studies available up to december
  31, 2005
• This provisional grading has not been discussed
  at the conference by the full group

12
On behalf of the ECIL Organization Committee T
Calandra, H Einsele, R Herbrecht, P Ljungman, J
Maertens, C Viscoli and C Cordonnier OUR SINCERE
THANKS TO Astellas Pharma, BMS, Gilead
Sciences, GSK,, MSD, Pfizer, Schering Plough,
Wyeth and Zeneus Pharma
13
The ECIL 1 conclusions are presented in a series
of 6 sets of slides
14
ECIL 1 2005 No. delegates per country
FINLAND 1
SWEDEN 2
NORWAY 1
IRELAND 2
DENMARK 1
UNITED KINGDOM 3
NETHERLANDS 2
GERMANY 5
BELGIUM 5
CZECH REPUBLIC 1
LUXEMBOURG 1
SLOVAK REPUBLIC 1
AUSTRIA 1
SWITZERLAND 3
HUNGARY 3
FRANCE 7
SLOVENIA 1
CROATIA 1
PORTUGAL 1
ITALY 6
SPAIN 3
TURKEY 1
GREECE 1
ISRAEL 3
15
(No Transcript)
16
(No Transcript)